Cargando…
PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428695/ http://dx.doi.org/10.1097/01.HS9.0000975820.37624.bc |
| _version_ | 1785090530470789120 |
|---|---|
| author | Qiu, Lihua Wang, Tingyu Sun, Xiuhua Su, Hang Cao, Junning LI, Zhi-Ming Song, Yuqin Zhang, LI LI, Dengju Wu, Huijing Zhang, Wei LI, Junmin Zhou, Keshu Zhou, Hui Yang, Yu LI, Zhifeng Cen, Hong Cai, Zhen Zhang, Zhihui Fu, Weijun Jin, Jie LI, Fei Wu, Weixin Gu, Xuekui Zhu, Weiliang Liu, Lihong LI, Zengjun Yi, Shuhua Qiu, Lugui |
| author_facet | Qiu, Lihua Wang, Tingyu Sun, Xiuhua Su, Hang Cao, Junning LI, Zhi-Ming Song, Yuqin Zhang, LI LI, Dengju Wu, Huijing Zhang, Wei LI, Junmin Zhou, Keshu Zhou, Hui Yang, Yu LI, Zhifeng Cen, Hong Cai, Zhen Zhang, Zhihui Fu, Weijun Jin, Jie LI, Fei Wu, Weixin Gu, Xuekui Zhu, Weiliang Liu, Lihong LI, Zengjun Yi, Shuhua Qiu, Lugui |
| author_sort | Qiu, Lihua |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428695 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104286952023-08-17 PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL Qiu, Lihua Wang, Tingyu Sun, Xiuhua Su, Hang Cao, Junning LI, Zhi-Ming Song, Yuqin Zhang, LI LI, Dengju Wu, Huijing Zhang, Wei LI, Junmin Zhou, Keshu Zhou, Hui Yang, Yu LI, Zhifeng Cen, Hong Cai, Zhen Zhang, Zhihui Fu, Weijun Jin, Jie LI, Fei Wu, Weixin Gu, Xuekui Zhu, Weiliang Liu, Lihong LI, Zengjun Yi, Shuhua Qiu, Lugui Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428695/ http://dx.doi.org/10.1097/01.HS9.0000975820.37624.bc Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Qiu, Lihua Wang, Tingyu Sun, Xiuhua Su, Hang Cao, Junning LI, Zhi-Ming Song, Yuqin Zhang, LI LI, Dengju Wu, Huijing Zhang, Wei LI, Junmin Zhou, Keshu Zhou, Hui Yang, Yu LI, Zhifeng Cen, Hong Cai, Zhen Zhang, Zhihui Fu, Weijun Jin, Jie LI, Fei Wu, Weixin Gu, Xuekui Zhu, Weiliang Liu, Lihong LI, Zengjun Yi, Shuhua Qiu, Lugui PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL |
| title | PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL |
| title_full | PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL |
| title_fullStr | PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL |
| title_full_unstemmed | PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL |
| title_short | PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL |
| title_sort | pb2272: pi3kδ inhibitor linperlisib for patients with relapsed or refractory follicular lymphoma: subgroup analysis of a phase 2 trial |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428695/ http://dx.doi.org/10.1097/01.HS9.0000975820.37624.bc |
| work_keys_str_mv | AT qiulihua pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT wangtingyu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT sunxiuhua pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT suhang pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT caojunning pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT lizhiming pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT songyuqin pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT zhangli pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT lidengju pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT wuhuijing pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT zhangwei pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT lijunmin pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT zhoukeshu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT zhouhui pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT yangyu pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT lizhifeng pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT cenhong pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT caizhen pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT zhangzhihui pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT fuweijun pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT jinjie pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT lifei pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT wuweixin pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT guxuekui pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT zhuweiliang pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT liulihong pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT lizengjun pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT yishuhua pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial AT qiulugui pb2272pi3kdinhibitorlinperlisibforpatientswithrelapsedorrefractoryfollicularlymphomasubgroupanalysisofaphase2trial |